$ONTX News

Last published 2y ago

2y agoONTX TRAWTraws Pharma Announces New Employee Inducement GrantsGlobeNewswireNEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws", the "Company")) today announced it has granted equity awards to new employees who joined Traws in connection with the recent
2y agoONTXOnconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology CompanyGlobeNewswireClosing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets:
2y agoONTXOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024GlobeNewswireNEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
2y agoONTXOnconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell LymphomaGlobeNewswirePreclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings Early Phase 1/2
2y agoONTXOnconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i'sGlobeNewswireDifferentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved
2y agoONTXOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity ConferenceGlobeNewswireNEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
2y agoONTXOnconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoONTXOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsGlobeNewswireNarazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for
3y agoONTXOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023GlobeNewswireNEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLGlobeNewswirePreclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) --
3y agoONTXOnconova Expands Leadership Team with Two Key AppointmentsGlobeNewswireDr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova",
3y agoONTXPromising Preclinical Narazaciclib Data Presented at MCL MeetingGlobeNewswireData for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers NEWTOWN, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Onconova
3y agoONTXEncouraging Rigosertib Data Presented at EADV as Late BreakerGlobeNewswireNEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and
3y agoONTXOnconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV CongressGlobeNewswireNEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireNEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant LymphomaGlobeNewswireNEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual MeetingGlobeNewswireNEWTOWN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with
3y agoONTXOnconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint BlockadeGlobeNewswireNEWTOWN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with
3y agoONTXOnconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireNEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with
3y agoONTXOnconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial CancerGlobeNewswireShowcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m. ET NEWTOWN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Onconova
3y agoONTXOnconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerGlobeNewswirePrior data provide clinical proof-of-concept for narazaciclib's mechanism of action in endometrial cancer Preliminary data from trial's Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa., May 11, 2023 (GLOBE NEWSWIRE)
3y agoONTXOnconova Therapeutics to Present at the ISID International Epidermolysis Bullosa SymposiumGlobeNewswireNEWTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023GlobeNewswireNEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual MeetingGlobeNewswireNEWTOWN, Pa., April 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark GelderGlobeNewswireNEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products
3y agoONTXOnconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to RigosertibGlobeNewswireCollaboration builds off clinical data demonstrating rigosertib's activity against PLK1 and may inform a precision medicine approach towards rigosertib's evaluation in new indications Collaboration will leverage
3y agoONTXOnconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswireNEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients
3y agoONTXOnconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual MeetingGlobeNewswireNEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients
3y agoONTXOnconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023GlobeNewswireNEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients
3y agoONTXOnconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS ConferenceGlobeNewswireData suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations Data reveal potential targets
3y agoONTXOnconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell CarcinomaGlobeNewswireTwo of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin lesions First
3y agoONTXOnconova Therapeutics to Present at the 2023 Guggenheim Oncology ConferenceGlobeNewswireNEWTOWN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with
3y agoONTXOnconova Therapeutics Announces Participation in the Channelchek Takeaway SeriesGlobeNewswireNEWTOWN, Pa., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today
3y agoONTXOnconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of DirectorsGlobeNewswireNEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with
3y agoONTXOnconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor ConferenceGlobeNewswireNEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today
3y agoONTXOnconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth ConferenceGlobeNewswireNEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today
4y agoONTXOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022GlobeNewswireNEWTOWN, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with
4y agoONTXOnconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare ConferenceGlobeNewswireNEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the
4y agoONTXOnconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022GlobeNewswireData show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3 distinct and different KRAS mutations, confirming th
4y agoONTXOnconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireNEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the
4y agoONTXOnconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireNEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial
4y agoONTXOnconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022GlobeNewswireNEWTOWN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the
4y agoONTXOnconova Therapeutics Announces Key Management PromotionsGlobeNewswireMark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development NEWTOWN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (N
4y agoONTXOnconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib's Differentiated Inhibitory and Improved Safety Profile in Preclinical ModelsGlobeNewswireNEWTOWN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of an ab
4y agoONTXOnconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireNEWTOWN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial
4y agoONTXOnconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022GlobeNewswireNEWTOWN, Pa., May 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the C
4y agoONTXOnconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual MeetingGlobeNewswireNEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an a
4y agoONTXOnconova Therapeutics to Present at the Next Generation Kinase Inhibitors SummitGlobeNewswireNEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Sil
4y agoONTXOnconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireNEWTOWN, Pa., March 17, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financia
4y agoONTXOnconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022GlobeNewswireNEWTOWN, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company inten